Cynata Therapeutics (ASX: CYP) is developing a scalable stem cell product from a single blood donation.
Stem cells are like the Wild Card in a game of Uno… they can become anything.
Because of this unique property, stem cells are incredibly valuable for research and therapy.
But the challenge is that there is no scalable way to secure them - either through embryos, human placenta, or adult bone marrow - each solution has its own unique challenges.
But CYP has a process to create multiple stem cells from a single blood donor.
